Alcohol use disorder represents a significant human health problem that leads to substantial loss of human life and financial cost to society. Currently available treatment options do not adequately address this human health problem, and thus, additional therapies are desperately needed. The endocannabinoid system has been shown, using animal models, to modulate ethanol-motivated behavior, and it has also been demonstrated that chronic ethanol exposure can have potentially long-lasting effects on the endocannabinoid system. For example, chronic exposure to ethanol, in either cell culture or preclinical rodent models, causes an increase in endocannabinoid levels that results in down-regulation of the cannabinoid receptor 1 (CB 1 ) and uncoupling of this receptor from downstream G protein signaling pathways. Using positron emission tomography (PET), similar downregulation of CB 1 has been noted in multiple regions of the brain in human alcoholic patients. In rodents, treatment with the CB 1 inverse agonist SR141716A (Rimonabant), or genetic deletion of CB 1 leads to a reduction in voluntary ethanol drinking, ethanol-stimulated dopamine release in the nucleus accumbens, operant selfadministration of ethanol, sensitization to the locomotor effects of ethanol, and reinstatement/relapse of ethanol-motivated behavior. Although the clinical utility of Rimonabant or other antagonists/inverse agonists for CB 1 is limited due to negative neuropsychiatric side effects, negative allosteric modulators of CB 1 and inhibitors of endocannabinoid catabolism represent therapeutic targets worthy of additional examination.
Introduction
Alcohol dependence is a highly prevalent disorder, which affects an estimated eight million Americans and inflicts a tremendous cost (in excess of $223.5 billion annually) to society (Bouchery et al., 2011; Grant et al., 2004) . Pharmaceutical treatments for alcohol dependence include the use of the opioid receptor antagonist naltrexone, and the broadlyacting drug, acamprosate. While naltrexone has been shown clinically to reduce alcohol intake and relapse (Foa et al., 2013; Kranzler et al., 2004; Latt et al., 2002 ), acamprosate appears to be more effective, compared to placebo, at increasing the percent of abstinent days (Mason et al., 2006) . A recent meta-analysis of the efficacy of both naltrexone and acamprosate for alcohol treatment demonstrated that these effects, though significant, are modest. Only 12-19% of individuals treated with naltrexone and 7-13% treated with acamprosate had better outcomes compared to those treated with placebo (Bouchery et al., 2011; Grant et al., 2004; Kranzler and Van Kirk, 2001 ). These studies illustrate the limitations of currently available pharmacotherapies and emphasize the need to expand therapeutic options for treating alcohol dependence.
Here we review the most current evidence demonstrating that ethanol can modulate endocannabinoid system (ECS) signaling in preclinical rodent models. Our review complements and builds on other excellent reviews on the interactions between the ECS and alcohol (Pava and Woodward, 2012) . Preclinical rodent models have been used to show that genetic and pharmacological inhibition of ECS signaling can profoundly reduce voluntary ethanol consumption, reward for (2-AG), 2-arachidonoyl-glycerol; (Δ 9 -THC), delta-9-tetrahydrocannabinol; (AA), Alko Alcohol preferring; (ABHD), alpha/beta hydrolase domain-containing protein; (ADE), alcohol deprivation effect; (AEA), Narachidonoylethanolamine; (CB 1 ), cannabinoid receptor 1; (CB 2 ), cannabinoid receptor 2; (CPP), conditioned place preference; (DAG), diacylglycerol; (DID), drinking in the dark; (DTs), delirium tremens; (ECS), endocannabinoid system; (EPSP), excitatory postsynaptic potential; (FAAH), fatty-acid amide hydrolase; (FR), fixed-ratio; (GIRK), G protein-coupled inward rectifying potassium channel; (GLAST), glutamate aspartate transporter; (GPR55), G protein-coupled receptor 55; (HIC), handling-induced convulsions; (KO), knock-out; (LORR), loss of righting reflex; (MAGL), monoacylglycerol lipase; (MAPK), mitogen-activated protein kinase; (msP), Marchigian Sardinian alcoholpreferring rat; (NAc), nucleus accumbens; (NADA), N-arachidonoyl dopamine; (NAPE), N-acylphosphatidylethanolamine; (NAT), N-acetyltransferase; (noladin ether), 2-arachidonoyl glyceryl ether; (NP), non alcohol preferring; (P), alcohol preferring; (PE), phosphatidylethanolamine; (PET), positron emission tomography; (PFC), pre-frontal cortex; (PLA 2 ), phospholipase-A 2 ; (PLC), phospholipase C; (PLD), phospholipase-D; (PR), progressive ratio; (PSR), Pavlovian spontaneous recovery; (SA), self-administration; (sNP), Sardinian alcohol non-preferring; (sP), Sardinian alcohol preferring; (SR1), SR141716A; (O-arachidonoyl ethanolamine), virodhamine; (VGCC), voltage-gated calcium channel; (VTA), ventral tegmental area.
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